findmyKOL
Clinical trialNCT06550141RecruitingPhase 2Interventional

Emapalumab Prevention of CAR-T Cell Associated Toxicities

SponsorMarcela V. Maus, M.D.,Ph.D.Enrollment28Diffuse Large B Cell LymphomaFollicular LymphomaHigh-grade B-cell LymphomaLarge B-cell LymphomaPrimary Mediastinal Large B-cell LymphomaRefractory Non-Hodgkin Lymphoma+1 more conditions
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This research study involves assessing the impact of emapalumab as preventative management of CAR-T related cytokine release syndrome in participants with Non-Hodgkin's lymphoma (NHL). The research study involves the following study interventions: * Fludarabine and cyclophosphamide (Lymphodepleting Chemotherapy) * Axicabtagene Ciloleucel * Emapalumab
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Dana-Farber Cancer Institute

    Boston, Massachusetts, United States

    Not, yet, recruiting
  • Massachusetts General Hospital

    Boston, Massachusetts, United States

    Matthew Frigault, MD →
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Axicabtagene ciloleucel →Cyclophosphamide →Emapalumab →Fludarabine →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
18 Sept 2024
Primary completion
1 Aug 2026
Completion
1 Aug 2027
Last update posted
14 Nov 2025
Registered enrollment
28
Registry id
NCT06550141
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.